Opdivo Qvantig™ FDA Approved for Subcutaneous Use in Adult Solid Tumor Indications Bristol Myers Squibb (NYSE: BMY) recently announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo…
Tivic Health CEO’s Letter to Shareholders Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company pioneering bioelectronic medicine, has released its annual letter from the CEO to shareholders, highlighting…
Sensorion Completes Enrollment of First Cohort in Audiogene Phase 1/2 Trial Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company focused on developing innovative therapies for hearing loss disorders, has…
Anebulo Pharmaceuticals announces positive update and capital raise for Selonabant Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company focused on developing innovative treatments for acute cannabinoid-induced toxicities, has announced…
Cervical Cancer : NERLYNX® Added to NCCN Guidelines for HER2-Mutation Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company focused on advancing cancer treatments, has announced that the National Comprehensive Cancer…
Exicure, Inc. (Nasdaq: XCUR, “Exicure” or the “Company”), today announced that its stockholders approved a second investment of $8.7 million from HiTron Systems Inc. (“HiTron”), a publicly listed company on…
JCR Pharmaceuticals Co., Ltd. (TSE 4552) today announced the dosing of the first patient in its Phase III clinical trial of JR-142 (INN: redalsomatropin alfa) in Japan. This marks a…
Bruker has announced the installation of a 1.2 GHz Ascend™ Nuclear Magnetic Resonance (NMR) spectrometer at the Swiss High-field NMR Facility, a collaborative research center jointly operated by the University…
MIRAILAB BIOSCIENCE Inc. (Headquarters: Chuo-ku, Tokyo; CEO: Megumi Tanaka) has partnered with Global Ocean Distribution Pte Ltd (Headquarters: Circular Road; Director: Getty Poon) to introduce its premium supplement brand MIRAI…
Sorriso Pharmaceuticals, a biopharmaceutical company focused on developing novel oral antibodies for immune-mediated diseases, today announced positive results from its Phase 1b clinical trial of SOR102. This oral, dual-acting biologic…
LimmaTech Biologics AG, a clinical-stage biotech company focused on developing vaccines for life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to…
Vivani Medical, Inc. (Nasdaq: VANI), an innovative biopharmaceutical company specializing in novel, ultra long-acting drug implants, today announced the initiation of screening and enrollment for its first-in-human clinical trial, LIBERATE-1™,…